Optimisation of cardiovascular risk factors in a dedicated cardio-oncology clinic for men with prostate cancer commencing androgen deprivation therapy

Clicks: 1
ID: 323296
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #106 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Patients with prostate cancer commenced on androgen deprivation therapy (ADT) have increased cardiovascular (CV) risk. Despite this, CV risk is often under-recognised and under-treated upon ADT initiation. Dedicated cardio-oncology (CO) services may facilitate systematic CV risk assessment and optimisation in this high-risk population. Purpose To investigate the feasibility and early outcomes of CV risk optimisation through a dedicated CO clinic in patients with prostate cancer receiving ADT. Method Patients with prostate cancer treated with ADT were reviewed prospectively in the dedicated CO clinics at a Victorian tertiary cardiac centre between 01/07/23–30/06/25. Data from electronic records collected on baseline CV comorbidities, cardiac investigations, medication changes, new CV diagnoses/interventions, mortality and trends in CV risk markers. Results 16 patients with 23 reviews (mean age 75.9±9.7years, median follow up 6.1±4.7months) were included. Baseline CV comorbidities were common (94% hypertension, 63% dyslipidaemia, 63% diabetes, 56% heart failure, 50% ischaemic heart disease, 50% with smoking history). 94% patients have CV medication modifications (total 38 modifications – 34% heart failure therapies, 24% statins, 18% antiplatelets/anticoagulants). Coronary artery disease was diagnosed in 6/8 patients without a pre-existing history. 2/16 patients required revascularisation (one patient needing percutaneous coronary intervention and one patient with coronary artery bypass grafting). During follow-up, median reductions were observed in total cholesterol (11.6%), LDL-cholesterol (18.3%), systolic blood pressure (12.4%) and HbA1c (2.1%). There was one cardiac admission and one cardiac-related death during follow up. Conclusion CV risk is elevated in patients with prostate cancer treated with ADT. CV risk optimisation can be feasibly achieved through a dedicated CO clinic which may have benefits in reducing CV complications.
Reference Key
openalex_W7172322558 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors H S Yap, A Abeydeera, U Pathak, J Lee, S X Tan, D Pook, W Ranasinghe, S Ramkumar
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.133
URL
https://doi.org/10.1093/eurheartjsupp/suag097.133
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.